EUVIMEDEUVIMED entdecken
Crossref

Enoximone alleviates atopic dermatitis-like skin inflammation via inhibition of type 2 T helper cell development

Jin Yong Song, Yeon Jin Lee, Su Hyun Lee, Ji-Yun Lee

International Immunopharmacology · 2024-12 · 142 · 113189

DOI: 10.1016/j.intimp.2024.113189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Jin Yong Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Th2 Cells, Dinitrochlorobenzene, Skin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is an inflammatory skin disease that affects approximately 15-20 % of the children and 1-3 % of the adults worldwide. Corticosteroids and calcineurin inhibitors are used in AD therapy; however, they cause various side effects. Current studies focus on novel therapeutic targets such as phosphodiesterases (PDEs) to mitigate AD. However, the relationship between PDE3 inhibitors and AD has not yet been reported. This study aimed to investigate the therapeutic effects and pharmaceutical mechanisms of enoximone (Enox), a PDE3 inhibitor. Mice were stimulated with 2,4-dinitrochlorobenzene (DNCB) to induce AD-like skin inflammation and were topically treated with Enox for 2 weeks. Treatment with Enox reduced the dermatitis score, skin water loss, IgE production, and expression of cytokines and chemokines that were elevated by DNCB. Histologically, Enox treatment reduced the skin thickness and the infiltration of various inflammatory cells, including macrophages, mast cells, eosinophils, and type 2 T helper (Th2) cells. HuT78, a human T cell line, was used to investigate the differentiation of T cells into Th2 cells. Enox treatment decreased the expression of Th2 cytokines and GATA3, a Th2 cell marker in HuT78, and suppressed signaling pathways that play a crucial role in Th2 cell differentiation. Collectively, the results demonstrate that Enox alleviates AD-like skin inflammation by inhibiting T-cell development. Thus, Enox may be a therapeutic candidate for the treatment of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicTh2 CellsDinitrochlorobenzeneSkinCytokinesAnimalsHumansMiceMice, Inbred BALB CCell DifferentiationCell LineDisease Models, AnimalFemaleImmunoglobulin EGATA3 Transcription FactorAnti-Inflammatory Agents

Stichwörter der Autor:innen

AllergyChronic diseaseEczemaSkin inflammationT-cell

Substanzen

DinitrochlorobenzeneCytokinesImmunoglobulin EGATA3 Transcription FactorAnti-Inflammatory Agents

Autor:innen und Institutionen

  • College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
  • College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea. Electronic address: jylee98@cau.ac.kr.

Zitieren

APA

Song, J. Y., Lee, Y. J., Lee, S. H., & Lee, J. Y. (2024). Enoximone alleviates atopic dermatitis-like skin inflammation via inhibition of type 2 T helper cell development. International Immunopharmacology, 142, 113189. https://doi.org/10.1016/j.intimp.2024.113189

Vancouver

Song JY, Lee YJ, Lee SH, Lee JY. Enoximone alleviates atopic dermatitis-like skin inflammation via inhibition of type 2 T helper cell development. International Immunopharmacology. 2024;142:113189. doi:10.1016/j.intimp.2024.113189

BibTeX
@article{Song2024,
  author = {Song, Jin Yong and Lee, Yeon Jin and Lee, Su Hyun and Lee, Ji-Yun},
  title = {Enoximone alleviates atopic dermatitis-like skin inflammation via inhibition of type 2 T helper cell development},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {142},
  pages = {113189},
  doi = {10.1016/j.intimp.2024.113189}
}
Kostenlos starten →